Testing stem cell particles for retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Diagnosed with retinitis pigmentosa, a genetic eye disease that causes vision loss
- Your better eye sees only a small central area (20 degrees or less of vision)
- Your worse eye has vision between 6/18 and 6/120 on a standard eye chart
- A test called electroretinogram shows little or no electrical activity in your worse eye
- You do not have blood-borne infections (like HIV, hepatitis B/C, or HTLV) or other serious health problems such as bleeding disorders or autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a single injection of umbilical cord stem cells around the eye can safely help slow or improve vision loss from retinitis pigmentosa, a genetic eye disease. It also checks how long any benefits might last, using regular eye tests and a quality-of-life survey.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
This trial tests whether stem cells from donated umbilical cord tissue can slow down or stop vision loss in people with retinitis pigmentosa, a condition that causes progressive blindness. You would receive these cells as injections around your eye and will be closely monitored with several vision tests.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This Phase 1/2 study tests a gene therapy treatment (BS01) in people with retinitis pigmentosa to try to improve or preserve vision. You may be a candidate if your vision in at least one eye is quite limited and you haven’t had certain gene therapies before.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.